Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
About this item
Full title
Author / Creator
MK-6482-004 Investigators , Jonasch, Eric , Donskov, Frede , Iliopoulos, Othon , Rathmell, W. Kimryn , Narayan, Vivek K , Maughan, Benjamin L , Oudard, Stephane , Else, Tobias , Maranchie, Jodi K , Welsh, Sarah J , Thamake, Sanjay , Park, Eric K , Perini, Rodolfo F , Linehan, W. Marston and Srinivasan, Ramaprasad
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The cause of von Hippel–Lindau disease is excess activity of the HIF-2α pathway. A total of 61 patients with renal cell carcinoma and other proliferative manifestations of the hypoxia-induced signaling pathway received belzutifan, which inhibits the HIF-2α pathway. Nearly half the patients with renal cell carcinoma had a response to treatment, and...
Alternative Titles
Full title
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2602077080
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2602077080
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2103425
